According to a media release from the American Association for Cancer Research (AACR), Stand Up to Cancer (SU2C) and the Prostate Cancer Foundation (PCF) are to invest approximately $10 million into a second prostate cancer Dream Team award over the next 3 years.
This SU2C-PCF Prostate Dream Team Translational Cancer Research Grant will go to work on “Targeting adaptive pathways in metastatic treatment-resistant prostate cancer” in a project to be co-led by Eric Small, MD, a professor of medicine and urology and chief of the division of hematology and oncology at the University of California, San Francisco (UCSF), and Owen Witte, MD, an investigator at the Howard Hughes Medical Institute and distinguished professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles (UCLA).
According to a statement by Dr. Small in the media release,
Despite an unprecedented increase in the number of drugs that have been approved for the treatment of advanced prostate cancer, our patients still develop resistance to these agents, and still die from progressive disease.
This SU2C-PCF project will help identify the causes of resistance in an individual patient, and help us tailor therapy for that patient. The project is predicated on early work from Dr. Phil Febbo, also at UCSF, who developed a genetic signature in prostate cancer patients that was subsequently used to direct therapy, and who was instrumental in crafting this proposal.
A first prostate cancer Dream Team award was funded by SU2C and PCF earlier this year.